NASM North American Scientific (MM)

North American Scientific, Inc. (Nasdaq:NASM) announced today that it will issue results for the second quarter of fiscal year 2008, which ended April 30, 2008, at market close on Wednesday, June 25, 2008. The Company will host an investor conference call to review its second quarter fiscal year 2008 financial results and latest corporate developments, beginning at 1:30 p.m. PDT/4:30 p.m. EDT on Wednesday, June 25, 2008. The dial-in number for the conference call is 866-202-0886 for domestic participants and 617-213-8841 for international participants, using the pass code 68823629. A taped replay of the call will be available beginning approximately one hour after the call�s conclusion and will remain available for seven days. It can be accessed by dialing 888-286-8010 for domestic callers and 617-801-6888 for international callers, using the pass code 14989109. A live webcast of North American Scientific�s conference call will be available over the Internet through its website at www.nasmedical.com in the Investor Center. For those who cannot listen to the live webcast, a replay of the call will be available at the same site shortly after the call. About North American Scientific North American Scientific is a leader in radiation therapy in the fight against cancer. Its innovative products provide physicians with tools for the treatment of various types of cancers. They include Prospera� brachytherapy seeds and SurTRAK� needles and strands used primarily in the treatment of prostate cancer. In addition, the Company has been gaining clinical experience with its first generation ClearPath� multi-channel catheter breast brachytherapy devices in 2007, and intends to launch the second generation devices in 2008. They are the only such devices approved for both high dose and continuous release, or low dose, radiation treatments. The devices are designed to provide flexible, precise dose conformance and an innovative delivery system that is intended to offer the more advanced form of brachytherapy for the treatment of breast cancer. Please visit www.nasmedical.com for more information. Statements included in this release that are not historical facts may be considered forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company including, but not limited to, the impact of competitive products and pricing, technological changes, changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements, the ability of the Company to successfully directly market and sell its products, uncertainties relating to patent protection and regulatory approval, the stable supply of appropriate isotopes, research and development estimates, market opportunities, risks associated with strategic opportunities or acquisitions the Company may pursue and the risk factors included in the Company�s filings with the Securities and Exchange Commission. Any forward-looking statements contained in this news release speak only as of the date of this release, and the Company undertakes no obligation to revise or update any forward-looking statements, whether as a result of new information, future results or otherwise.